Sector News

Pfizer, BioNTech strike COVID-19 deal, commit multiple R&D sites to vaccine development

March 17, 2020
Life sciences

Pfizer has teamed up with BioNTech to co-develop and distribute a mRNA vaccine against COVID-19 outside of China. The partners plan to use multiple R&D sites in the U.S. and Germany to accelerate the progress of a vaccine that is due to begin clinical testing in humans by the end of April.

BioNTech and Pfizer have both referred to talks about a COVID-19 partnership in recent weeks, most recently yesterday when the German mRNA specialist issued a statement on the status of its vaccine and related deal-making. The latest advance in the partnering discussions clears BioNTech and Pfizer to immediately start working together on a vaccine against the novel SARS-CoV-2 coronavirus.

To initiate the alliance, Pfizer and BioNTech have executed a material transfer and collaboration agreement and agreed on a letter of intent covering the co-development and distribution of the vaccine, code-named BNT162, outside of China. Fosun Pharma is partnered on the vaccine in China.

The paperwork signed by BioNTech and Pfizer to date lacks details that ordinarily would be central to a co-development agreement, most notably the final financial terms of the relationship. However, with the number of COVID-19 cases rising rapidly in countries around the world, Pfizer and BioNTech have decided not to let the financial details hold up the collaboration.

Over the next few weeks, BioNTech and Pfizer will finalize the financial terms and details of how the development, manufacturing and commercialization will work. The execution of the collaboration agreement means a joint effort to push the vaccine forward will advance in parallel to those talks.

While full details of how the partnership will work are still being finalized, the broad plan is for Pfizer and BioNTech to commit resources at multiple R&D sites in the U.S. and Germany to the project. The involvement of Pfizer, a far larger company than BioNTech, could potentially unlock resources that accelerate the progress of the vaccine.

“We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible,” Mikael Dolsten, Pfizer’s chief scientific officer, said in a statement.

BioNTech expects to start testing the vaccine in humans late next month and already has capacity in place to produce materials for the global clinical trial. The partnerships with Fosun and Pfizer are intended to ensure the program retains momentum right through to commercial availability.

Having a vaccine in the clinic by late April would represent a fast turnaround by historical standards. Yet, the timeline puts BioNTech well behind another of the main mRNA companies, Moderna, which began testing its vaccine in healthy volunteers this week. Both companies have benefited from mRNA vaccine platforms that are faster than conventional ways of developing prophylactic shots.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach